Impaired handling of iron Nutritional, Metabolic, Endocrine Disorders of mineral metabolism
Conditions
Interventions
Main study:
Three intervention groups:
1. 2 mg riboflavin for eight weeks
2. 4 mg riboflavin for eight weeks
3. Placebo for eight weeks
Bioavailability study:
32 volunteers from the main study rand
Sponsors
University of Sheffield (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Women aged 19 to 25 years 2. Low milk consumption (less than 200 ml a day) 3. Healthy 4. Marginal riboflavin deficiency as measured by an Erythrocyte Glutathione Reductase Activation Coefficient of greater than 1.4;Inclusion criteria: 1. Women aged 19 to 25 years 2. Low milk consumption (less than 200 ml a day) 3. Healthy 4. Marginal riboflavin deficiency as measured by an Erythrocyte Glutathione Reductase Activation Coefficient of greater than 1.4
Exclusion criteria
Exclusion criteria: 1. Use of multivitamin or iron supplements (within last three months) 2. Diagnosed gastrointestinal disorders 2.1. coeliac disease 2.2. ulcerative colitis 2.3. Crohns disease 2.4. inflammatory bowel disease 3. Blood donors 4. Haemochromatosis 5. Pregnancy;Exclusion criteria: 1. Use of multivitamin or iron supplements (within last three months) 2. Diagnosed gastrointestinal disorders 2.1. coeliac disease 2.2. ulcerative colitis 2.3. Crohns disease 2.4. inflammatory bowel disease 3. Blood donors 4. Haemochromatosis 5. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study, measured at baseline and after eight weeks intervention: 1. Measures of iron and haematological status: 1.1. Ferritin 1.2. Haemoglobin 1.3. Mean Corpuscular Volume (MCV) 1.4. Mean Corpuscular Haemoglobin Concentration (MCHC) 1.5. Red Blood Cells (RBC) 1.6. Haematocrit 1.7. Zinc Protoporphyrin (ZPP) 1.8. Soluble Transferrin Receptor (sTFR) Bioavailability study, additional outcomes measured at baseline and two weeks after dose of isotopic iron (repeated on two separate occasions before and after main study): Incorporation of Fe58 into erythrocytes.;Main study, measured at baseline and after eight weeks intervention: 1. Measures of iron and haematological status: 1.1. Ferritin 1.2. Haemoglobin 1.3. Mean Corpuscular Volume (MCV) 1.4. Mean Corpuscular Haemoglobin Concentration (MCHC) 1.5. Red Blood Cells (RBC) 1.6. Haematocrit 1.7. Zinc Protoporphyrin (ZPP) 1.8. Soluble Transferrin Receptor (sTFR) Bioavailability study, additional outcomes measured at baseline and two weeks after dose of isotopic iron (repeated on two separate occasions before and after main study): Incorporation of Fe58 into erythrocytes. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lowering of plasma homocysteine.;Lowering of plasma homocysteine. | — |
Countries
United Kingdom
Contacts
Public Contact; ;
;
Outcome results
None listed